There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF–Research Report) with bullish sentiments.
Confident Investing Starts Here:
Telix Pharmaceuticals (TLPPF)
In a report released today,Tara Bancroftfrom TD Cowen maintained aBuyrating on Telix Pharmaceuticals, with a price target ofA$35.00. The company’s shares closed last Wednesday at $17.00.
According toTipRanks.com, Bancroft ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of-9.9% and a 37.1% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Whitehawk Therapeutics.
Currently, the analyst consensus on Telix Pharmaceuticals is a Strong Buy with an average price target of $22.66.
(20min delay)